Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-05
1997-02-11
Grumbling, Matthew V.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548471, 548467, 5483121, 514183, 514213, 514308, 514310, 514414, 514397, 514318, 514323, 514253, 514254, 514218, 514272, 514273, 514307, 514339, 546140, 546143, 546194, 546200, 5462771, 540476, 540594, 540597, 540596, 540470, 540575, 544295, 544363, 544344, 544373, 544331, 544292, A61K 3140, A61K 3133, C07D20944, C07D21702, C07D26316
Patent
active
056021682
ABSTRACT:
Disclosed are compounds of the formula ##STR1## or the pharmaceutically acceptable salts thereof wherein the 6-membered A ring may be optionally substituted with up to four groups independently selected from halogen, hydroxy, lower alkyl, or lower alkoxy;
REFERENCES:
patent: 5298520 (1994-03-01), Baker et al.
patent: 5409931 (1995-04-01), Caprathe et al.
May et al., Arzneimittel-Forschung, 30(9), 1487-1493, (1980).
de Costa Brian
He Xiao-Shu
Wasley Jan W. F.
Grumbling Matthew V.
Neurogen Corporation
LandOfFree
1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342617